Product Information
AMLODIPINE-VALSARTAN 5-160 MG is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.2640 per EA under NDC 00378172193. Its NADAC has been published 597 times since Apr 29, 2015.
FDA first approved this application on Mar 30, 2015. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 160 mg/1; mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
00378172193
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
AMLODIPINE BESYLATE; VALSARTANApproval Type
Generic (ANDA)
FDA Application
ANDA090483FDA Approved
3/30/2015
TE Code
AB
On Market Since
3/30/2015
Pharmacological Classes
Price Statistics
The NADAC for AMLODIPINE-VALSARTAN 5-160 MG has been published 597 times since Apr 29, 2015, and over the history we have for it it has declined 93.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2640 per EA |
|---|---|
| All-time high | $4.2444 (Jun 10, 2015) |
| All-time low | $0.2640 (Sep 23, 2026) |
| 52-week high | $0.4755 |
| 52-week low | $0.2640 |
| Median price | $0.4623 |
| Average price | $0.5119 |
| Largest weekly change | -66.9% (Jul 22, 2015) |
| Weeks tracked | 597 |
| Tracking since | Apr 29, 2015 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the AMLODIPINE AND VALSARTAN market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
AMLODIPINE AND VALSARTAN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin 2 Receptor Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of AMLODIPINE-VALSARTAN 5-160 MG?
The current National Average Drug Acquisition Cost (NADAC) for AMLODIPINE-VALSARTAN 5-160 MG, manufactured by Mylan Pharmaceuticals Inc., is $0.2640 per EA (NDC 00378172193), effective Sep 30, 2026.
How has the price of AMLODIPINE-VALSARTAN 5-160 MG changed over time?
Over the history we have for it, the NADAC for AMLODIPINE-VALSARTAN 5-160 MG has declined 93.7%. It has been tracked across 597 weekly CMS publications since Apr 29, 2015.
What are the highest and lowest recorded NADAC prices for AMLODIPINE-VALSARTAN 5-160 MG?
Since Apr 29, 2015, the NADAC for AMLODIPINE-VALSARTAN 5-160 MG has ranged from a low of $0.2640 (Sep 23, 2026) to a high of $4.2444 (Jun 10, 2015), with a median of $0.4623 per EA.
Are there cheaper alternatives to AMLODIPINE-VALSARTAN 5-160 MG?
No other NADAC-published product currently shares the active ingredient and strength of AMLODIPINE-VALSARTAN 5-160 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures AMLODIPINE-VALSARTAN 5-160 MG?
AMLODIPINE-VALSARTAN 5-160 MG (NDC 00378172193) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.